67193-97-9

Basic information

• Product Name: 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE
• Synonyms: 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE;7-Hydroxy-2H-1,4-benzoxazin-3(4H)-one;7-Hydroxy-4H-benzo[1,4]oxazin-3-one;7-hydroxy-3,4-dihydro-2H-1,4-benzoxazin-3-one;2H-1,4-Benzoxazin-3(4H)-one, 7-hydroxy-;7-hydroxy-4H-1,4-benzoxazin-3-one
• CAS NO: 67193-97-9
• Molecular Formula: C₈H₇NO₃
• Molecular Weight: 165.147
• Mol File: 67193-97-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 208-209℃
• Appearance: /
• Density: 1.396
• CAS DataBase Reference: 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(67193-97-9)
• EPA Substance Registry System: 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE(67193-97-9)

Safety Data

• Hazardous Substances Data: 67193-97-9(Hazardous Substances Data)

Usage

General Description

7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is a chemical compound with a molecular formula C8H5NO3. It is an organic compound that belongs to the oxazinone class of chemicals. 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE consists of a benzene ring fused to an oxazine ring, with a hydroxyl group attached to the benzene ring at the 7 position. 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE is a versatile intermediate in organic synthesis and can be used in the preparation of various pharmaceuticals and agrochemicals. It can also be utilized as a building block in the production of dyes and other specialty chemicals. 7-HYDROXY-2H-BENZO[B][1,4]OXAZIN-3(4H)-ONE may have potential applications in the fields of medicine, agriculture, and materials science.

InChI:InChI=1S/C8H7NO3/c10-5-1-2-6-7(3-5)12-4-8(11)9-6/h1-3,10H,4H2,(H,9,11)

Upstream product

• 34781-86-7 4-aminoresorcinol hydrochloride 
• 79-04-9 chloroacetyl chloride 
• 1219130-57-0 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 321436-06-0 7-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 38191-34-3 2-amino-5-bromophenol 
• 27684-84-0 5-bromo-2-nitrophenol 
• 101908-41-2 2-chloro-N-(2,4-dimethoxyphenyl)acetamide 
• 771-26-6 4-hydroxy-2H-1,4-benzoxazin-3-one 
• 37682-31-8 ethyl o-nitrophenoxyacetate 
• 33252-96-9 4-acetoxy-(2H)-1,4-benzoxazin-3(4H)-one 
• 164471-20-9 methyl (5-benzyloxy-2-nitrophenoxy)acetate 
• 122005-15-6 chloro-acetic acid-(2,4-dihydroxy-anilide) 
• 89441-81-6 7-acetoxy-2H-1,4-benzoxazin-3(4H)-one 

Downstream Products

• 6238-91-1 [2-(3,4-Dichloro-benzoylamino)-5-hydroxy-phenoxy]-acetic acid 
• 104535-37-7 7-hydroxy-3,4-dihydro-2H-1,4-benzoxazine 
• 1149370-96-6 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol hydrochloride 
• 85112-64-7 N-cyclohexyl-N-methyl-4-[(2,3-dihydro-3-oxo-1,4-benzoxazin-7-yl)oxy]butyramide 

Relevant articles and documents

HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS

The present application relates to novel heterocycle derivatives of Formula (I), to processes for preparing them, pharmaceutical compositions containing them, and their use thereof in the treatment or prevention of acute and/or chronic neurological disord

ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS

Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.

Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis

Angiogenesis is vital for solid tumor growth, and its prevention is a proven strategy for the treatment of disease states such as cancer. The vascular endothelial growth factor (VEGF) pathway provides several opportunities by which small molecules can act as inhibitors of endothelial proliferation and migration. Critical to these processes is signaling through VEGFR-2 or the kinase insert domain receptor (KDR) upon stimulation by its ligand VEGF. Herein, we report the discovery of 2,3-dihydro-1,4-benzoxazines as inhibitors of intrinsic KDR activity (IC50 50 a potent (KDR: a promising platform for generating kinase-based antiangiogenic therapeutic agents.